NADPH oxidase-1 suppression prolongs the antidepressant-like effect of ketamine.
Molecular Psychiatry July 1, 2026 Waki Nakajima, Tetsu Arisawa, Susumu Jitsuki et al. 1 citation
Subanesthetic doses of ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, produce rapid and robust antidepressant effects in patients with treatment-resistant depression (TRD). However, after a single administration, the therapeutic benefit is short-lived, and strategies to maintain its efficacy remain unclear. This study focused on the glutamate...